BofA reiterates Merck stock rating on Terns acquisition potential

Merck agreed to acquire Terns Pharmaceuticals for approx. $6.7B ($53.00/share cash), a 31% premium to the 60-day VWAP, and will record a ~$5.8B ($2.35/share) in-process R&D charge in Q2; the deal is expected to close in Q2 2026. Analysts reacted positively overall: BofA reiterated Buy with a $132 PT, Barclays reiterated Overweight with a $140 PT, Morgan Stanley kept Equalweight with a $109 PT, and H.C. Wainwright downgraded Terns to Neutral. Management views TERN-701 as having multi-billion dollar peak sales potential to bolster Merck’s oncology franchise ahead of Keytruda LOE in 2029–2031; Merck shares trade near $119.63 (close to a 52-week high) and sector peers (e.g., Enliven) jumped on the news.

Analysis

Large-cap pharma accelerating mid-sized, near-clinic bolt-ons changes the optionality calculus across the oncology ecosystem. Buyers are buying time-to-revenue rather than platform upside, which tightens demand for Phase 2/near-Phase 3 assets and pushes up valuations and competition for CRO/CDMO capacity over the next 6–18 months.

That tightening produces two second-order effects: (1) smaller biotech free cash burn profiles become more binary — either get bought at higher bids or face financing runs as sponsor budgets reallocate to M&A targets; (2) service providers with scalable capacity will see pricing power and margin expansion, while niche labs face margin compression and longer lead times. These dynamics compress the pickup window for acquirers (fewer truly de-risked assets available) and raise execution risk on integration and trial timelines.

The biggest under-appreciated tail risk is payer/price compression for new IO and targeted oncology entrants — even a successful Phase 3 can face constrained uptake if combos are discounted or HTA thresholds tighten. Near-term earnings will be noisy from deal accounting and timing of milestone recognition; catalysts to watch are R&D readouts, regulatory filings and any visible cadence of additional bolt-on deals, with event clusters expected across quarters rather than instant value realization.

Key Decisions for Investors

• Long MRK equity (12-month horizon): size a 1–2% portfolio position to capture M&A optionality and pipeline derisking. Protect with a 10% OTM put (6–9 month expiry) or buy a 12-month put to cap downside; target 15–25% upside if subsequent readouts/bolt-ons land, stop-loss at 12% realized drawdown.
• Relative-value pair: Long MRK / Short XBI (equal notional, 6–12 months): isolates large-cap M&A premium vs broad mid-cap biotech financing stress. Expect positive carry if acquirers continue to bid; unwind if small-cap index outperforms by >8% intra-quarter.
• Event-driven options on small-cap oncology (e.g., ELVN): buy 9–12 month calls sized 0.5–1% portfolio to capture takeover rerate potential after heightened sector M&A appetite. Risk limited to premium; target 3x return if bidding interest resumes.
• Volatility capture: sell MRK near-term (30–60 day) call spreads after any deal announcement to collect IV compression, size to 25–30% of directional long exposure. Hedge structural downside with longer-dated puts to avoid gap risk from trial or regulatory disappointments.